01—Abstract
Summary
Summary of the 8-K filed January 30, 2026. Cited figures are marked; the original filing is the authoritative source.
Amgen Inc. (AMGN) announced on January 30, 2026, the termination of its License and Collaboration Agreement with Kyowa Kirin Co., Ltd., originally dated June 1, 2021.
This termination is set to become effective upon receiving the necessary regulatory approvals, signaling a potential shift in Amgen's strategic partnerships and pipeline development. While the specific reasons for termination and the financial implications are not detailed in this filing, investors should monitor future communications for updates on how this development might impact Amgen's ongoing research and development efforts, particularly concerning any products or technologies covered under the terminated agreement. The agreement with Kyowa Kirin, if significant, could have implications for revenue streams, cost-sharing, or market access for certain therapeutic areas.
02—Key points
Key Highlights
- Amgen Inc. entered into a Termination Agreement with Kyowa Kirin Co., Ltd.
- The agreement effectively terminates the License and Collaboration Agreement originally signed on June 1, 2021.
- The termination is contingent upon receiving regulatory approval.
- The filing was made on January 30, 2026.
- The termination date of the original agreement is specified as June 1, 2021.
- Exhibit 10.1, the Termination Agreement, is filed with the SEC, with certain confidential portions omitted.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The main purpose of this 8-K filing is to announce Amgen Inc.'s entry into a Termination Agreement with Kyowa Kirin Co., Ltd., which will terminate their existing License and Collaboration Agreement.
When will the termination of the License and Collaboration Agreement become effective?
The termination will become effective upon receipt of regulatory approval.
What was the original agreement that is being terminated?
The original agreement being terminated is the License and Collaboration Agreement dated June 1, 2021, between Amgen Inc. and Kyowa Kirin Co., Ltd.
Are the financial details or reasons for the termination disclosed?
This 8-K filing does not disclose the specific financial implications or the detailed reasons behind the termination of the agreement. Further details may be provided in subsequent filings or communications.
04—Continue